TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06255912
Drug: LTC004 + MIL-97
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
Study: NCT06137144
Drug: AZD3470
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
Study: NCT06524583
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² intravenous (IV) at Day 1 every 3 weeks (4 cycles)
Study: NCT05705336
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
Study: NCT04833426
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical gel containing testosterone
Study: NCT04833426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel without active substance
Study: NCT05896371
Drug: 177Lu-PSMA-I&T - escalating renal absorbed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized 177Lu-PSMA-I\&T injected activity
Study: NCT05896371
Drug: 177Lu-PSMA-I&T - recommended phase 2 regime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized 177Lu-PSMA-I\&T injected activity
Study: NCT05372653
Drug: OPA-15406
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% or 1% ointment, topical, twice daily, for 52 weeks
Study: NCT06393374
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
Study: NCT04985812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo to JNJ-67484703.
Study: NCT05646381
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04951609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo orally.
Study: NCT04619420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to JNJ-63733657 will be administered by IV infusion.
Study: NCT06459193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT05879978
Drug: Obrixtamig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obrixtamig
Study: NCT05633602
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care chemotherapy
Study: NCT04550104
Drug: AZD1390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04550104
Drug: AZD5305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06277336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial SIAD induction:~* Oral water intake of 30ml/kg body weight in one hour (timepoint -2 to timepoint -1)~* Intravenous bolus of desmopressin 4 μg i.v. (Minirin®, Ferring AG) (timepoint -1)~* 300ml NaCl 0.45% (B. Braun Medical AG) over 1 hour (timepoint -1 to 0)~Study infusion (timepoint 0 to timepoint +3):~* 180-ml NaCl 0.45% infusion (placebo) over 3 hours (60ml per h)
Study: NCT06479226
Drug: cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash
Normalized name: cetylpyridinium chloride / zinc chloride Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthrinse
Study: NCT05039515
Drug: IPN60130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release capsule containing high dose of the drug substance.
Study: NCT05039515
Drug: IPN60130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release capsule containing low dose of the drug substance.
Study: NCT05039515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be supplied as powder filled hard capsules
Study: NCT05591118
Drug: Anticoagulant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive anticoagulation for a minimum of 3 months.
Study: NCT05661851
Drug: Investigational Lubricating Eye Drop in a Novelia® bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT05661851
Drug: Blink® Tears eye Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Product
Study: NCT05841758
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during a 12 months double blind placebo-controlled period
Study: NCT06085924
Drug: SoC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 treatment as per government guidance
Study: NCT05835479
Drug: Co-Trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Study: NCT04232657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Study: NCT06533865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.
Study: NCT06533865
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One intravenous infusion
Study: NCT05773950
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.
Study: NCT05055050
Drug: UGN-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical 200 mg /50 ml x 1 dose
Study: NCT04717713
Drug: steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid injection at surgical location
Study: NCT04717713
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline injection at surgical location
Study: NCT04958031
Drug: CVL-871 3.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
Study: NCT04958031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD, oral (tablet), once per day for 12 weeks
Study: NCT05500898
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, multiple doses of DWP16001
Study: NCT04772313
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Study: NCT05183243
Drug: GH21 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
Study: NCT06472908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one pill a day, oral intake
Study: NCT05245084
Drug: D013, D326, D337
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05925114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral capsule that looks identical to S-309309 capsule
Study: NCT04853329
Drug: CPO107
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD20-CD47 Bispecific Fusion Protein
Study: NCT05625568
Drug: VYNT-0126
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for oral administration once daily
Study: NCT06784999
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
Study: NCT05121246
Drug: MB05 (Proposed palivizumab biosimilar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IM dose of 3 mg/kg
Study: NCT05121246
Drug: EU-Synagis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IM dose of 3 mg/kg
Study: NCT05121246
Drug: US-Synagis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IM dose of 3 mg/kg
Study: NCT04711824
Drug: Physicians Choice systemic chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
Study: NCT05233761
Drug: Defined CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CBD and 8 mg Terpenes administered as two small capsules.
Study: NCT05784129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT05233761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.
Study: NCT04711109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT05676034
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX0035
Study: NCT06202612
Drug: SHR0302 quick release tablets
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 quick release tablets 8 mg
Study: NCT06202612
Drug: SHR0302 sustained-release tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 sustained-release tablets 10 mg
Study: NCT04829318
Drug: SSRI/SNRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Study: NCT05626023
Drug: Human TH-SC01 cell injection
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of human TH-SC01 cell injection
Study: NCT04677530
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally.
Study: NCT05057806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be administered orally once per day for 3 months
Study: NCT04630028
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT03643367
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Included patients randomized in control group, intravenouse sedation is continued with propofol
Study: NCT06624228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive placebo at pre-specified time points.
Study: NCT04936308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo as SC injection.
Study: NCT05041842
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
Study: NCT04903197
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAY736 is a fully human IgG1 monoclonal antibody (mAb) which targets the B cell activating factor receptor (BAFF-R) expressed on the surface of differentiated B cells and modulates their function.
Study: NCT04547166
Drug: HLX04、
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Study: NCT05268003
Drug: Mini-hyper CVD
Normalized name: Hyper-Sal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05169814
Drug: Micro/nanobubble (MNB) - Irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
Study: NCT05169814
Drug: Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
Study: NCT06138834
Drug: High-dose Y-6 sublingual tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take two Y-6 sublingual tablets (each tablet contains 25 mg Cilostazol and 6 mg Dexborneol), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
Study: NCT06138834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take two tablets of placebo of Y-6 sublingual tablets (each tablet contains 0 mg Cilostazol and 0.06 mg Dexborneol to simulate the cool taste of Y-6 sublingual tablets when taken), and two halves Cilostazol mimicry tablets (each tablet contains 0 mg Cilostazol) for 28 days continuously.
Study: NCT04827901
Drug: XEN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 10 mg capsules
Study: NCT04827901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT06623461
Drug: Standard of Care Immune Checkpoint Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any ICB (single agent or combination) may be used that is commercially available, Health Canada-approved and publically funded for the treatment of participants with advanced, unresectable or metastatic melanoma. The treatment decision for choice of ICB regimen will be made prior to randomization and cannot be changed after enrollment
Study: NCT05713799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06434233
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.
Study: NCT06434233
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.
Study: NCT02446379
Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
Study: NCT06136507
Drug: FRSW107
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
Study: NCT05514548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Matching size and number of tablets
Study: NCT06028438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously.
Study: NCT06441266
Drug: KeraStat cream
Normalized name: Kerastat Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions. The intervention is a topical cream applied at least twice daily starting at start of radiation therapy until 1-month from the end of radiation therapy completion
Study: NCT04269993
Drug: Cannabis: placebo and medium THC/medium CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis was administered to participants (placebo and medium THC/medium CBD).
Study: NCT06559527
Drug: NNC0487-0111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will administer a single dose of NNC0487-0111 subcutaneously using NovoPen®4 by injection into a skinfold on the abdomen.
Study: NCT05094336
Drug: Comparator AMG 193 Test Tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
Study: NCT06457789
Drug: [18F]F-AraG PET imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a static whole-body PET scan following a \[18F\]F-AraG injection.
Study: NCT05867121
Drug: RO7496353
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7496353 will be administered as per the schedules specified in the respective arms.
Study: NCT05867121
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered as per the schedules specified in the respective arms
Study: NCT05628233
Drug: SENS-401 (R-Azasetron Besylate)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SENS-401 ((R)-azasetron besylate) B.I.D. up to 23 weeks: 1 week prior to the initiation of the cisplatin treatment, during the whole duration of the chemotherapy treatment (estimated to last up to 18 weeks) and 4 weeks after stopping chemotherapy.
Study: NCT06382948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo orally once daily
Study: NCT06003218
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be infused with doses adjusted to maintain a Richmond Agitation-Sedation Scale between -2 to -1 during surgery.
Study: NCT05564377
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05564377
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05272150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo as subcutaneous injection.
Study: NCT00626613
Drug: Risperdal,reminyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
Study: NCT06312137
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Study: NCT06563375
Drug: NP-101
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT05474729
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: minocycline capsule 100mg per day orally
Study: NCT05363605
Drug: [225Ac]-FPI-1966
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
Study: NCT04885634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of volume-matched placebo once weekly
Study: NCT05045469
Drug: dian dao san
Approvals — FDA: no, EMA: no, PMDA: no
Description: dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
Study: NCT05296837
Drug: Doxycycline 40 MG ( 20mg twice daily)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submicrobial dose doxycycline (40mg) to be administered as 20mg twice daily
Study: NCT05296837
Drug: Doxycycline 200 MG ( 100 mg twice daily)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg dose doxycycline to be administered as 100mg twice daily
Study: NCT05296837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered in tablet form twice daily
Study: NCT06384547
Drug: VRDN-001 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 infusions of VRDN-001 3 mg/kg
Study: NCT04988555
Drug: Enzomenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSP-5336 orally
Study: NCT06116916
Drug: KHK4951
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK4951 eye drop for 36 weeks until end of the trial
Study: NCT06485648
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: G(glucocorticoid) + i.v. Normal saline